Author:
Williams Adam Dale Newman,Wood Fiona,Gillespie David,Couzens Zoë,Hughes Kathryn,Hood Kerenza
Abstract
Abstract
Background
HIV pre-exposure prophylaxis (PrEP) is a medication that prevents the acquisition of HIV. It has been targeted towards men who have sex with men (MSM). Since its introduction there have been concerns raised around changes in sexual behaviour such as increased condomless anal intercourse (CAI), leading to an elevation in sexually transmitted infections (STIs). With antimicrobial resistant strains of STIs rising, there are concerns that PrEP may be contributing to this growth. This study aims to understand how MSM conceptualise the relationship between PrEP, STIs and antimicrobial resistance (AMR).
Methods
Twenty semi-structured interviews were conducted online using Zoom. Participants include a mix of PrEP related experiences (never used, currently use, previously used). Reflexive thematic analysis was undertaken by the lead author with 10% of transcripts double coded.
Results
MSM in Wales have positive views and a good knowledge of PrEP and awareness of bacterial STIs. PrEP is perceived by many to lead to a reduction in condom use and increase in STIs but reported condom use behaviours presented to be stable in terms of PrEP initiation. PrEP use is influenced by increased concern for HIV and minimal concern for bacterial STIs. Awareness of AMR STIs was lacking.
Conclusions
There is a belief that PrEP use will lead to an increase in STI rates through reduced condom use, despite reported behaviours often being stable in relation to PrEP initiation, PrEP stigma may be influencing this dichotomy. Concern and awareness for resistant STIs is low, with little association to PrEP.
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference24 articles.
1. McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): Effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387:53–60. https://doi.org/10.1016/S0140-6736(15)00056-2.
2. Molina JM, Charreau I, Spire B, et al, ANRS IPERGAY Study Group. Efficacy, safety, and effect on sexual behaviour of on-demand preexposure prophylaxis for HIV in men who have sex with men: An observational cohort study. Lancet HIV 2017;4:402–e410. https://doi.org/10.1016/s2352-3018(17)30089-9.
3. Public Health Wales. Pre-exposure prophylaxis for HIV provision in Wales. Jan 2018. Available from: https://phw.nhs.wales/files/publications/hiv-data-reports-for-wales/prep-in-wales/prep-activity-inforgraphic-july-2017-march-2018-pdf/
4. Public Health Wales. Pre-exposure prophylaxis (PREP) for HIV - Service Guide. 2018; 2. Available from: https://phw.nhs.wales/files/publications/hiv-data-reports-for-wales/prep-in-wales/prep-wales-service-guide-pdf/
5. Quaife M, MacGregor L, Ong JJ, Gafos M, Torres-Rueda S, Grant H, Terris-Prestholt F, Vickerman P. Risk compensation and STI incidence in PrEP programmes. Lancet HIV. 2020;7(4):222–3. https://doi.org/10.1016/S2352-3018(19)30333-9.